Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds and their associated drug formulations to destroy various cancers in Canada, the United States, and internationally. It operates in two divisions, Photo Dynamic Therapy and Therapeutic Laser Technology. The company also designs, manufactures, and distributes super-pulsed cool laser technology for the treatment of pain for knees, nerves, muscles, and joints, as well as for in off-label use. Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of healing, as well as TLC-1000 and TLC-2000 accessories. The company is also developing TLD-1433, an anti-cancer drug, which is in Phase 1B clinical trial for non-muscle invasive bladder cancer. The company sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1995 and is headquartered in Toronto, Canada.
Industry, Sector and Symbol
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
Phone+1-416-6995273
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$2.26 million
Profitability
Miscellaneous
Employees20
OptionableOptionable
Theralase Technologies (CVE:TLT) Frequently Asked Questions
What is Theralase Technologies' stock symbol?
Theralase Technologies trades on the Canadian Venture Exchange (CVE) under the ticker symbol "TLT."
When is Theralase Technologies' next earnings date?
Has Theralase Technologies been receiving favorable news coverage?
News articles about TLT stock have been trending somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Theralase Technologies earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Theralase Technologies' key competitors?
Some companies that are related to Theralase Technologies include Bioquell (BQE), Consort Medical (CSRT), Corindus Vascular Robotics (CVRS), Deltex Medical Group (DEMG), Ekf Diagnostics (EKF), Immunodiagnostic Systems (IDH), InspireMD (NSPR), LiDCO Group (LID), Lucid (LCDX), Medaphor Group (MED), Smith & Nephew (SN), Verisante Technology (VRS) and Zecotek Photonics (ZMS).
Who are Theralase Technologies' key executives?
Theralase Technologies' management team includes the folowing people:
- Dr. Arkady Mandel, Interim CEO & Chief Scientific Officer
- Ms. Kristina Hachey, Chief Financial Officer
- Mr. Roger John Dumoulin-White, Director of Bus. Devel.
- Mr. David M. Groves B.A, Pres of World Trade Division
- Dr. James R. Andrews (ASMI), M.D., Chairman of Medical & Scientific Advisory Board and Medical Director (Age 76)
How do I buy shares of Theralase Technologies?
Shares of TLT and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Theralase Technologies' stock price today?
One share of TLT stock can currently be purchased for approximately C$0.30.
What is Theralase Technologies' official website?
How can I contact Theralase Technologies?
Theralase Technologies' mailing address is 1945 Queen St E, TORONTO, ON M4L 1H7, Canada. The company can be reached via phone at +1-416-6995273.
MarketBeat Community Rating for Theralase Technologies (CVE TLT)
MarketBeat's community ratings are surveys of what our community members think about Theralase Technologies and other stocks. Vote "Outperform" if you believe TLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
